Asian Activities Report for June 8, 2011: Agenix (ASX:AGX) On Track To Begin Clinical Trials In China For The New Hepatitis B Drug

Sydney, June 8, 2011 AEST (ABN Newswire) - Major Asian markets all had a negative start in today's trading. The S&P/ASX200 lost 0.80% to 4529.9 in early trade. Nikkei 225 dropped 0.40% to 9,404.71. Hang Seng Index slid 0.99% to 22641.75, while Shanghai Composite was down 0.58% to 2728.44.

Companies

China-focused drug development and diagnostic company Agenix (ASX:AGX) said that the Company was on track to begin clinical trials in China for its lead Hepatitis B drug, AGX 1009. Agenix will file a formal application with China's State Food and Drug Administration in the second quarter of 2012 and anticipates approval to begin Phase I human studies in late 2012.

Central Asia Resources Limited (ASX:CVR) announced a substantial increase in the Indicated and Inferred Resources for its Dalabai Gold Project in the Republic of Kazakhstan. Total Indicated and Inferred Resources for Dalabai have increased 28% to 124,000 ounces of gold. Construction of the Dalabai mine remains on schedule for completion and start of production in Q4 2011.

Tanami Gold NL (ASX:TAM) announced a further substantial increase in its gold Mineral Resources to 2.30 million ounces of gold. Experienced mining engineer, Mr Don Harper, has been appointed as Tanami Gold's new Chief Operating Officer, to oversee the Company's target to lift production from Western Tanami and commence production at the Central Tanami Project by mid-2012.

Corazon Mining Limited (ASX:CZN) said today that initial assay results from the Lynn Lake nickel sulphide project in Canada confirmed the existence of a high-grade nickel/copper sulphide discovery. Drilling is currently at a depth of approximately 1,000 metres and will continue to 1,250 metres to test for further mineralisation in July.

Contact

Asia Business News Tel: +61-2-9247-4344 http://www.abnnewswire.net